AI-Driven Off-Target Toxicity Prediction Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides an AI-Driven Off-Target Toxicity Prediction Service to address critical challenges in cell therapy development, including high clinical attrition rates, unpredictable off-tumor toxicities, and the difficulty of identifying cross-reactive TCR or CAR candidates across the human proteome. This service enables comprehensive safety profiling through a multi-agent AI architecture and large-scale autoreactome analysis. By screening more than 730,000 human-derived peptides and applying advanced pHLA presentation modeling, Creative Biolabs delivers high-confidence predictions that de-risk therapeutic candidates and ensure safety before clinical translation.

Introduction

Off-target toxicity caused by unintended cross-reactivity remains a major safety concern in immunotherapy development. Recent studies demonstrate that proteome-wide computational screening combined with AI modeling can effectively identify hidden cross-reactive epitopes beyond simple sequence similarity. By integrating antigen presentation prediction and tissue expression data, these approaches significantly enhance early-stage risk assessment and improve therapeutic specificity.

Service

Creative Biolabs provides systematic screening of therapeutic candidates across the full human proteome to identify potential cross-reactive targets and early off-target binding risks that may cause toxicity in critical tissues. Our multi-dimensional assessment integrates sequence similarity, structural features, epitope binding prediction, and antigen presentation likelihood for a holistic evaluation. We deliver data-driven, prioritized risk profiles to guide target selection, molecular engineering, and affinity optimization, offering clear, actionable insights to support go/no-go decisions, candidate ranking, and design refinement while reducing late-stage failure and enhancing clinical safety.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Proteome-Wide Screening Platform	AI-Based Binding and Cross-Reactivity Modeling
Systematic scanning of the human proteome for sequence and motif similarity. Identification of candidate off-target epitopes across thousands of proteins.	Machine learning models to predict binding affinity and interaction likelihood. Structural and physicochemical feature integration for improved accuracy.
Antigen Presentation Prediction	Tissue Expression Risk Analysis
Evaluation of peptide processing and presentation potential. Prioritization of biologically relevant off-target risks.	Integration of transcriptomic and proteomic datasets. Identification of high-risk tissues (e.g., heart, brain, lung).

Our Workflow

The process begins with the client providing the Required Starting Materials, which typically include the lead TCR/CAR-binding sequence and the specific HLA restriction alleles.

Workflow of AI-Driven Off-Target Toxicity Prediction Service. (Creative Biolabs Original)

Clients receive a comprehensive Toxicity Risk Assessment Report, including a ranked list of the top 20 high-risk off-target peptides and a Tissue Distribution Heatmap illustrating the expression of parent proteins across vital organs.

Core Benefits

Multi-Agent AI Coordination: Simultaneous orchestration of target discovery, toxicity prediction, and rational molecular design agents.
Cross-Reactivity Scanning for Rare Variants: Integration of Single Nucleotide Polymorphisms to ensure safety across diverse patient populations.
TCRm and Bispecific Antibody Triage: Specialized specificity assessment for antibody-based MHC-mimics and T-cell engagers.
Longitudinal Stability Analysis: Evaluating the persistence of autoantibody profiles to predict the long-term safety of B-cell/plasma cell-depleting therapies.
Customized In Silico Libraries: Creation of project-specific peptide databases focusing on specific organ systems or tumor microenvironments.

FAQs

Q: Can you predict toxicity for rare HLA alleles?

A: Yes. Our models incorporate structural encodings of the peptide-MHC groove, allowing us to generalize across common and rare allelic variants.

Q: Is this service applicable to solid tumor targets?

A: We specialize in identifying the subtle cross-reactivity risks associated with public neoantigens.

Q: What measures ensure AI accuracy?

A: We use uncertainty-aware filtering. If a candidate falls into a low-confidence regime, our system flags it for mandatory wet-lab validation.

Q: Does this service meet regulatory standards?

A: Our Safety Score gates and auditable decision logs are designed to provide the robust data packages required for applications and regulatory confidence.

Partner with Us

Creative Biolabs offers the industry's most comprehensive AI-Driven Off-Target Toxicity Prediction Service for immunotherapies. By integrating proteome-wide scanning, pHLA presentation modeling, and expert biological synthesis, our platform accurately identifies and quantifies potential off-target risks at the early development stage. It serves as a critical tool for research and development teams aiming to transition from experimental interventions to standardized, safe, and widely accessible immunotherapies. Contact our team today for more information and to discuss how we can support your project.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.